Atom | NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

Funder: National Institutes of Health

Due Dates: January 26, 2026 (Letter of Intent) | February 26, 2026 (Renewal/Resubmission/Revision) | January 26, 2027 (Letter of Intent) | February 26, 2027 (Renewal/Resubmission/Revision)

Funding Amounts: Up to $3,500,000 total costs per project (max 3 years; recommended not to exceed $1,166,667/year); up to $50,000 additional for Technical and Business Assistance (TABA) per project.

Summary: Supports small businesses in commercializing technologies for heart, lung, blood, and sleep disorders in rare diseases or young pediatric populations, bridging the gap between SBIR Phase II and market entry.

Key Information: Applicants must secure independent third-party investor funds equal to or exceeding one-third of requested NHLBI funds; projects must require eventual federal regulatory approval.

NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

Sign in to see full grant listing